In short
This article discusses the use of Lovo-B, a component of the investigational drug STC-1010, in clinical trials for patients with advanced or metastatic colorectal cancer. STC-1010 is being studied in combination with standard-of-care therapies to evaluate its safety and efficacy in treating this challenging form of cancer.
At a glance
- Drug Name
- STC-1010 (including Lovo-B as an active substance)
- Trial Phase
- Phase I/IIA
- Target Condition
- Unresectable locally advanced or metastatic colorectal cancer
- Trial Design
- Open-label, multicenter, dose-escalation and cohort-expansion
- Combination Therapy
- STC-1010 with standard-of-care treatments (e.g., mFOLFOX6 + bevacizumab)
- Primary Endpoints
- Safety profile, determination of recommended Phase 2 dose, progression-free survival at 12 months
- Key Eligibility Criteria
- Adults 18-75 years, specific tumor characteristics, adequate organ function
- Treatment Duration
- Induction phase (up to 8 cycles) followed by maintenance therapy
What is STC-1010?
STC-1010 is a new type of cancer treatment called immunotherapy. It is currently being studied as a potential treatment for advanced colorectal cancer. STC-1010 is also known as "Stimulated Tumor Cells-1010," which gives us a clue about how it works.
How does STC-1010 work?
STC-1010 is made up of specially prepared cancer cells. These cells come from different types of colorectal cancer cell lines, including HCT116, HT-29, and LOVO. The idea behind this treatment is to "stimulate" or activate your immune system to fight against colorectal cancer cells in your body.
Think of it like showing your immune system a "wanted poster" of the cancer cells. By exposing your immune system to these stimulated tumor cells, the hope is that it will learn to recognize and attack similar cancer cells in your body.
What conditions does STC-1010 treat?
STC-1010 is being studied for the treatment of unresectable locally advanced or metastatic colorectal cancer. Let's break down what this means:
- Unresectable: This means the cancer cannot be completely removed by surgery.
- Locally advanced: The cancer has spread from where it started to nearby tissue or lymph nodes.
- Metastatic: The cancer has spread to other parts of the body, far from where it started.
- Colorectal cancer: This is a cancer that starts in the colon (large intestine) or rectum.
Clinical Trial Details
The clinical trial for STC-1010 is called the "BreAK CRC trial". It is divided into two main parts:
- Phase I: This part of the trial aims to test the safety of STC-1010 and find the right dose to use.
- Phase IIA: This part will test how well STC-1010 works in treating colorectal cancer.
In both phases, STC-1010 will be given along with other cancer treatments. These include chemotherapy drugs (like FOLFOX) and a drug called bevacizumab, which helps stop tumors from growing new blood vessels.
Who can participate in the trial?
The trial is looking for adults aged 18-75 with advanced colorectal cancer. There are specific requirements for participation, including:
- Having a type of colorectal cancer that can't be removed by surgery
- Being in overall good health besides the cancer
- Having normal blood cell counts and organ function
- Not having certain other medical conditions
It's important to note that there are many other specific criteria that doctors use to determine if someone is eligible for the trial. If you're interested in participating, you should discuss this with your oncologist.
Potential Benefits and Risks
As with any experimental treatment, there are potential benefits and risks to participating in this trial:
Potential benefits:
- Access to a new treatment that might be more effective than current options
- Close monitoring by a team of medical professionals
- Contributing to medical research that could help future cancer patients
Potential risks:
- Unknown side effects from the new treatment
- The treatment might not be effective
- Time commitment for treatments and follow-up appointments
It's crucial to discuss these potential benefits and risks with your healthcare team before deciding to participate in any clinical trial.